サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1326556

生物製剤受託開発の世界市場規模調査＆予測、由来別、製品サービス別、疾患適応症別、地域別分析、2023-2030年

Global Biologics Contract Development Market Size Study & Forecast, By Source, by Product Service, by Disease Indication and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
生物製剤受託開発の世界市場規模調査＆予測、由来別、製品サービス別、疾患適応症別、地域別分析、2023-2030年
出版日: 2023年07月28日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の生物製剤受託開発市場は、2022年に約60億8,000万米ドルと評価され、予測期間2023～2030年には10.5%以上の健全な成長率で成長すると予測されています。

生物製剤受託開発とは、生物製剤や治療薬の開発・製造サービスを開発・製造受託機関（CDMO）や研究開発受託機関（CRO）に委託することを指します。生物製剤は、タンパク質、抗体、ワクチン、遺伝子治療など、生体由来の複雑な分子です。生物学的生産への先端技術の採用が増加していることが、市場成長の触媒として作用しています。さらに、製薬会社による医薬品開発手法の増加、食品医薬品局による医薬品承認率の上昇、標的薬理療法の使用増加、個別化薬物療法への要望の高まりなども、市場成長の要因となっています。

さらに、神経疾患、婦人科疾患、がん、眼科疾患、心血管疾患などの疾患の急増が、世界の市場開拓に寄与しています。2022年の世界保健機関（WHO）によると、がんは世界の主な死因のひとつであり、2020年には1,000万人以上が死亡しています。2020年のキャンサー・トゥモローの予測によると、2020年には約1,930万人のがん患者が報告され、この数字は2040年までに3,020万人に増加すると予測されています。このような状況において、ヘルスケアCDMOは患者ケアにおいて重要な役割を担っています。なぜなら、多くのバイオファーマ企業は、疾病治療のための新薬やファースト・イン・クラスの製品の開発を志しているからです。さらに、生物学的製剤開発のための先端技術の採用の増加、新興諸国における臨床試験のための有利な環境、先進的な生物学的製剤を開発するための現地企業との提携、契約、合併の増加、バイオ医薬品セクターにおける製造の柔軟性を高める開発の増加は、予測期間中に市場成長のための有利な機会を提供すると予想されます。しかし、生物製剤の製造工程にかかるコストが高いことや、これらの製品の使用法に関する理解が不足していることが、生物製剤受託開発産業の成長を制限しています。

世界の生物製剤受託開発市場の調査対象とした主な地域には、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカが含まれます。北米は2021年に市場をリードすると予想されています。戦略的な提携や買収、専門的な試験サービスに対する需要の高まりが市場を牽引しています。開発業務受託機関（CDO）の成長は、主にこの地域の臨床試験およびアウトソーシング活動の増加に起因しています。さらに、慢性疾患の有病率の高さが、この地域における臨床試験の需要を大幅に促進しています。これらの要因が市場拡大の原動力となっています。アジア太平洋地域は、予測期間中に最も急成長する地域となる見込みです。世界のニーズに基づいて臨床試験の評価基準を更新するために、さまざまな規制機関の調整が行われているため、バイオテクノロジー企業はアジア太平洋地域に投資しています。

本調査の目的は、近年のさまざまなセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 世界の生物製剤受託開発市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 業界の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 世界の生物製剤受託開発市場力学

  • 生物製剤受託開発市場の影響分析（2020～2030年）
    • 市場促進要因
      • 様々な対象疾患の有病率の上昇
      • 製薬企業による医薬品開発手法の増加
      • 消費者による個別化医療への志向の高まり
    • 市場の課題
      • 生物製剤の製造工程における高コスト
    • 市場機会
      • 生物学的開発のための先端技術導入の増加
      • バイオ医薬品セクターにおける製造の柔軟性の向上

第4章 世界の生物製剤受託開発市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 世界の生物製剤受託開発市場：由来別

  • 市場スナップショット
  • 生物製剤受託開発の世界市場：由来別、実績 - ポテンシャル分析
  • 生物製剤受託開発の世界市場、由来別推定・予測：2020-2030年
  • 生物製剤受託開発市場、サブセグメント分析
    • 微生物
    • 哺乳類
    • その他

第6章 生物製剤受託開発の世界市場：製品サービス別

  • 市場スナップショット
  • 生物製剤受託開発の世界市場：製品サービス別、実績 - ポテンシャル分析
  • 生物製剤受託開発の世界市場：製品サービス別推定・予測2020～2030年
  • 生物製剤受託開発市場、サブセグメント別分析
    • 細胞株開発
    • プロセス開発
    • その他

第7章 生物製剤受託開発の世界市場、疾患適応症別

  • 市場スナップショット
  • 生物製剤受託開発の世界市場：疾患適応症別、実績 - ポテンシャル分析
  • 生物製剤受託開発の世界市場、疾患適応症別、2020年～2030年推定・予測
  • 生物製剤開発受託市場、サブセグメント分析
    • がん領域
    • 免疫疾患
    • 心血管疾患
    • 血液疾患
    • その他

第8章 生物製剤受託開発の世界市場、地域別分析

  • 主要国
  • 主な新興国
  • 生物製剤受託開発市場、地域別市場スナップショット
  • 北米
    • 米国
      • 由来別の推定・予測、2020-2030年
      • 製品サービス別の推定・予測、2020～2030年
      • 疾患適応症別の推定・予測、2020～2030年
    • カナダ
  • 欧州生物製剤受託開発市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋生物製剤受託開発市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの生物製剤受託開発市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第9章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • WuXi Biologics
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Abzena Ltd
    • Fujifilm Diosynth Biotechnologies
    • KBI Biopharma, Inc.
    • AGC Biologics
    • Thermo Fisher Scientific Inc.
    • Curia Global, Inc.
    • Genscript
    • Bionova Scientific, Inc.
    • BioXcellence（Boehringer Ingelheim Biopharmaceuticals GmbH）

第10章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Biologics Contract Development Market, report scope
  • TABLE 2. Global Biologics Contract Development Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Biologics Contract Development Market estimates & forecasts by Source 2020-2030 (USD Billion)
  • TABLE 4. Global Biologics Contract Development Market estimates & forecasts by Product Service 2020-2030 (USD Billion)
  • TABLE 5. Global Biologics Contract Development Market estimates & forecasts by Disease Indication 2020-2030 (USD Billion)
  • TABLE 6. Global Biologics Contract Development Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Biologics Contract Development Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Biologics Contract Development Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Biologics Contract Development Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Biologics Contract Development Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Biologics Contract Development Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Biologics Contract Development Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Biologics Contract Development Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Biologics Contract Development Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Biologics Contract Development Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. U.S. Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 18. U.S. Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 20. Canada Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 21. Canada Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 23. UK Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 24. UK Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 26. Germany Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 27. Germany Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 29. France Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 30. France Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 32. Italy Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 33. Italy Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 35. Spain Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 36. Spain Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 38. RoE Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 39. RoE Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 41. China Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 42. China Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 44. India Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 45. India Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 47. Japan Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 48. Japan Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 50. South Korea Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 51. South Korea Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 53. Australia Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 54. Australia Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 59. Brazil Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 60. Brazil Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 62. Mexico Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 63. Mexico Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 65. RoLA Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 66. RoLA Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. Saudi Arabia Biologics Contract Development Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 68. South Africa Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 69. RoMEA Biologics Contract Development Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. List of secondary sources, used in the study of global Biologics Contract Development Market
  • TABLE 71. List of primary sources, used in the study of global Biologics Contract Development Market
  • TABLE 72. Years considered for the study
  • TABLE 73. Exchange rates considered

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Biologics Contract Development Market, research methodology
  • FIG 2. Global Biologics Contract Development Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Biologics Contract Development Market, key trends 2022
  • FIG 5. Global Biologics Contract Development Market, growth prospects 2023-2030
  • FIG 6. Global Biologics Contract Development Market, porters 5 force model
  • FIG 7. Global Biologics Contract Development Market, pest analysis
  • FIG 8. Global Biologics Contract Development Market, value chain analysis
  • FIG 9. Global Biologics Contract Development Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Biologics Contract Development Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Biologics Contract Development Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Biologics Contract Development Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Biologics Contract Development Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Biologics Contract Development Market, regional snapshot 2020 & 2030
  • FIG 15. North America Biologics Contract Development Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Biologics Contract Development Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Biologics Contract Development Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Biologics Contract Development Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Biologics Contract Development Market 2020 & 2030 (USD Billion)

List of tables and figures are dummy in nature, final lists may vary in the final deliverable

目次

Global Biologics Contract Development Market is valued at approximately USD 6.08 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 10.5% over the forecast period 2023-2030. Biologics contract development refers to the outsourcing of development and manufacturing services for biologic drugs or therapies to contract development and manufacturing organizations (CDMOs) or contract research organizations (CROs). Biologics are complex molecules derived from living organisms, including proteins, antibodies, vaccines, and gene therapies. The rising adoption of advanced technology for biological production is acting as a catalyzing factor for market growth. Furthermore, increased drug development methods by pharmaceutical companies, increased drug approval rates by the Food and Drug Administration, increased use of targeted pharmacological therapies, and increased desire for personalized medication are some of the factors resulting in the increase in market growth.

In addition, the surging prevalence of diseases such as neurological illnesses, gynecological disorders, cancer, ophthalmic disorders, and cardiovascular disorders are contributing to the market development across the globe. According to World Health Organization in 2022, cancer is one of the main causes of death worldwide, accounting for over 10 million deaths in 2020. According to Cancer Tomorrow predictions in 2020, approximately 19.3 million cancer cases were reported in 2020, with this figure anticipated to climb to 30.2 million by 2040. In such circumstances, healthcare CDMOs play an important role in patient care because many biopharma companies aspire to develop novel medicines or first-in-class products for illness treatment. Furthermore, an increase in the adoption of advanced technologies for biologic development, a favorable environment for clinical trials in developing countries, an increase in the number of collaborations, contracts, and mergers with local players to develop advanced biologic products, and an increase in the development of greater manufacturing flexibility in the biopharmaceutical sector is expected to provide lucrative opportunities for market growth over the forecasting period. However, the high cost of biologics production processes, as well as a lack of understanding about the usage of these products, limit the growth of the biologics contract development industry.

The key regions considered for the Global Biologics Contract Development Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America is expected to lead the market in 2021. Strategic collaborations and acquisitions, as well as growing demand for specialized testing services, are driving the market. The growth of contract development organizations (CDOs) can be attributed mostly to the region's increased clinical trial and outsourcing activity. Furthermore, the high prevalence of chronic diseases is substantial fostering the demand for clinical studies in this region. These factors drive market expansion. Asia Pacific is expected to be the fastest growing region during the forecast period, because of different regulatory organization adjustments to update clinical trial evaluation standards based on global needs, biotechnology businesses are investing in the Asia Pacific region.

Major market players included in this report are:

  • WuXi Biologics
  • Abzena Ltd
  • Fujifilm Diosynth Biotechnologies
  • KBI Biopharma, Inc.
  • AGC Biologics
  • Thermo Fisher Scientific Inc.
  • Curia Global, Inc.
  • Genscript
  • Bionova Scientific, Inc.
  • BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Recent Developments in the Market:

  • In September 2020, Almac Group recently announced the beginning of a contract for testing and development services for biologics. The development and testing of new biologic products will benefit from this expansion.
  • In February 2020, Lake Pharma In., Inc. has announced the debut of combined chemistry and biologics services, for faster antibody-drug conjugates development solutions for the pharmaceutical and biotechnology sectors.

Global Biologics Contract Development Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Source, Product Services, Disease Indication, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Source:

  • Microbial
  • Mammalian
  • Others

By Product Service:

  • Cell Line Development
  • Process Development
  • Others

By Disease Indication:

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Biologics Contract Development Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Biologics Contract Development Market, by Source, 2020-2030 (USD Billion)
    • 1.2.3. Biologics Contract Development Market, by Product Service, 2020-2030 (USD Billion)
    • 1.2.4. Biologics Contract Development Market, by Disease Indication, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Biologics Contract Development Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Biologics Contract Development Market Dynamics

  • 3.1. Biologics Contract Development Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of various target diseases
      • 3.1.1.2. Increased drug development methods by pharmaceutical companies population
      • 3.1.1.3. Increased inclination for personalised medication by consumers
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of biologics production processes
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increase in the adoption of advanced technologies for biological development
      • 3.1.3.2. Increase in the development of greater manufacturing flexibility in the biopharmaceutical sector

Chapter 4. Global Biologics Contract Development Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Biologics Contract Development Market, by Source

  • 5.1. Market Snapshot
  • 5.2. Global Biologics Contract Development Market by Source, Performance - Potential Analysis
  • 5.3. Global Biologics Contract Development Market Estimates & Forecasts by Source 2020-2030 (USD Billion)
  • 5.4. Biologics Contract Development Market, Sub Segment Analysis
    • 5.4.1. Microbial
    • 5.4.2. Mammalian
    • 5.4.3. Others

Chapter 6. Global Biologics Contract Development Market, by Product Service

  • 6.1. Market Snapshot
  • 6.2. Global Biologics Contract Development Market by Product Service, Performance - Potential Analysis
  • 6.3. Global Biologics Contract Development Market Estimates & Forecasts by Product Service 2020-2030 (USD Billion)
  • 6.4. Biologics Contract Development Market, Sub Segment Analysis
    • 6.4.1. Cell Line Development
    • 6.4.2. Process Development
    • 6.4.3. Others

Chapter 7. Global Biologics Contract Development Market, by Disease Indication

  • 7.1. Market Snapshot
  • 7.2. Global Biologics Contract Development Market by Disease Indication, Performance - Potential Analysis
  • 7.3. Global Biologics Contract Development Market Estimates & Forecasts by Disease Indication 2020-2030 (USD Billion)
  • 7.4. Biologics Contract Development Market, Sub Segment Analysis
    • 7.4.1. Oncology
    • 7.4.2. Immunological Disorders
    • 7.4.3. Cardiovascular Disorders
    • 7.4.4. Hematological Disorders
    • 7.4.5. Others

Chapter 8. Global Biologics Contract Development Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Biologics Contract Development Market, Regional Market Snapshot
  • 8.4. North America Biologics Contract Development Market
    • 8.4.1. U.S. Biologics Contract Development Market
      • 8.4.1.1. Source breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Product Service breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Disease Indication breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Biologics Contract Development Market
  • 8.5. Europe Biologics Contract Development Market Snapshot
    • 8.5.1. U.K. Biologics Contract Development Market
    • 8.5.2. Germany Biologics Contract Development Market
    • 8.5.3. France Biologics Contract Development Market
    • 8.5.4. Spain Biologics Contract Development Market
    • 8.5.5. Italy Biologics Contract Development Market
    • 8.5.6. Rest of Europe Biologics Contract Development Market
  • 8.6. Asia-Pacific Biologics Contract Development Market Snapshot
    • 8.6.1. China Biologics Contract Development Market
    • 8.6.2. India Biologics Contract Development Market
    • 8.6.3. Japan Biologics Contract Development Market
    • 8.6.4. Australia Biologics Contract Development Market
    • 8.6.5. South Korea Biologics Contract Development Market
    • 8.6.6. Rest of Asia Pacific Biologics Contract Development Market
  • 8.7. Latin America Biologics Contract Development Market Snapshot
    • 8.7.1. Brazil Biologics Contract Development Market
    • 8.7.2. Mexico Biologics Contract Development Market
  • 8.8. Middle East & Africa Biologics Contract Development Market
    • 8.8.1. Saudi Arabia Biologics Contract Development Market
    • 8.8.2. South Africa Biologics Contract Development Market
    • 8.8.3. Rest of Middle East & Africa Biologics Contract Development Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. WuXi Biologics
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Abzena Ltd
    • 9.3.3. Fujifilm Diosynth Biotechnologies
    • 9.3.4. KBI Biopharma, Inc.
    • 9.3.5. AGC Biologics
    • 9.3.6. Thermo Fisher Scientific Inc.
    • 9.3.7. Curia Global, Inc.
    • 9.3.8. Genscript
    • 9.3.9. Bionova Scientific, Inc.
    • 9.3.10. BioXcellence (Boehringer Ingelheim Biopharmaceuticals GmbH)

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption